全球抗病毒藥物市場(2022-2028 年):市場預測(藥物類別、適應症、類型、年齡組)、區域前景、增長潛力、價格趨勢、COVID-19 的影響、市場份額
市場調查報告書
商品編碼
1067355

全球抗病毒藥物市場(2022-2028 年):市場預測(藥物類別、適應症、類型、年齡組)、區域前景、增長潛力、價格趨勢、COVID-19 的影響、市場份額

Antiviral Drugs Market Size By Drug Class, By Indication, By Type, By Age Group, Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028

出版日期: | 出版商: Global Market Insights Inc. | 英文 195 Pages | 商品交期: 2-3個工作天內

價格

在全球病毒感染激增的背景下,預計到 2028 年,抗病毒藥物市場將顯著增長。

根據跡象,活躍的研發活動預測流感行業在預測期內將以約 2.8% 的複合年增長率穩健增長。季節性流感的高複發率和持續的庫存變化產生了對藥物開發的需求,刺激了該行業的增長。按類型劃分,品牌製藥行業在 2021 年的市場份額超過 71%,預計在預測期內將呈現強勁增長。品牌藥物的高效性和廣泛的產品線預計將支持產品採用。

本報告探討了全球抗病毒藥物市場、市場定義和概述、新型冠狀病毒感染 (COVID-19) 和其他市場影響因素的分析、監管環境和市場規模。它總結了趨勢/預測、分類等各個類別如藥物類別/適應症/類型/年齡組/地區/主要國家、競爭環境、主要公司概況等。

目錄

第一章調查方法/調查範圍

第2章執行摘要

第三章抗病毒藥物產業的思考

  • 行業分類
  • 產業情況
  • 行業影響因素
    • 生長因子
    • 潛在風險和挑戰
  • 增長潛力分析
  • COVID-19:影響分析
  • 監管狀態
  • 波特分析
  • 競爭形勢
  • PESTEL 分析

第 4 章抗病毒藥物市場:按藥物類別

  • 主要趨勢
  • DNA聚合□抑製劑
  • 逆轉錄□抑製劑
  • 蛋白□抑□□製劑
  • 神經氨酸□抑製劑
  • 其他

第 5 章抗病毒藥物市場:按適應症

  • 主要趨勢
  • 流感
  • 艾滋病
  • 肝炎
  • 單純皰疹病毒(HSV)
  • 冠狀病毒感染
  • 其他

第 6 章抗病毒藥物市場:按類型

  • 主要趨勢
  • 品牌藥
  • 仿製藥

第 7 章抗病毒藥物市場:按年齡組

  • 主要趨勢
  • 成人
  • 兒童
  • 老人

第 8 章抗病毒藥物市場:按地區劃分

  • 主要趨勢
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第 9 章公司簡介

  • 競爭性儀表板
  • Gilead Sciences, Inc
  • Johnson & Johnson
  • GlaxoSmithKline
  • AbbVie, Inc
  • Merck & Co.,
  • Bristol Myers Squibb
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd
  • Cipla, Inc.
  • Mylan N.V.
Product Code: 4968

The antiviral drugs market is slated to witness notable expansion through 2028 driven by surging incidences of antiviral infections across the globe.

The onset of COVID-19 prompted massive R&D activities worldwide to find effective therapeutic remedies for the novel coronavirus infection. As a result, increased focus on the development of novel drugs for viral infections like COVID-19 has been favorable for the product landscape during the pandemic.

The antiviral drugs market has been categorized on the basis of drug class, indication, type, age group, and region. Based on drug class, the market has been further segregated into reverse transcriptase inhibitors, neuraminidase inhibitors, protease inhibitors, DNA polymerase inhibitors, and others.

The others sub-segment was valued at nearly USD 18 billion in 2021 and is anticipated to register solid revenue growth over 2022-2028 primarily driven by continuous developments and advancements in drug therapies. Combination therapy offers several advantages, such as high bioavailability, shelf life, and efficacy. Prevalent usage of combination therapy for enhanced patient outcomes is set to accelerate segmental growth through the assessment timeframe.

In terms of indication, the industry has been classified into HIV AIDS, influenza, herpes simplex virus (HSV), hepatitis, coronavirus infection, and others. The antiviral drugs market size from the influenza sub-segment is slated to witness robust expansion at about 2.8% CAGR between 2022 and 2028 on account of prominent R&D activities. High recurrence of seasonal flu as well as continuous changes in strain would create need for drug development, which is likely to stimulate segmental progress.

By type, the market has been bifurcated into generic and branded. In 2021, the branded sub-segment held more than 71% share in the market and is projected to observe strong growth over the review timeline. Greater effectiveness of branded drugs and extensive product pipelines are foreseen to boost product adoption. Moreover, strong presence of key market players is expected to positively influence segmental revenue in the coming years.

With respect to age group, the antiviral drugs market has been segmented into pediatric, adult, and geriatric. The geriatric sub-segment garnered over USD 20 billion in revenue in 2021 and is speculated to grow at a considerable rate through 2028. High prevalence of sexually transmitted diseases among the geriatric population, along with high healthcare spendings and presence of large patient pool, is primed to propel segmental expansion.

In the regional landscape, the Latin America antiviral drugs market accounted for around 3.7% of the overall industry revenue in 2021 and is estimated to reach a sizable revenue by the end of 2028 owing to increasing occurrences of COVID-19 and HIV, coupled with growing awareness regarding available treatments across the region. Furthermore, market participants are implementing several growth strategies to broaden their market footprints, which is forecast to promote market growth in LATAM in the future.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates and working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia Pacific
    • 1.2.4 Latin America
    • 1.2.5 MEA
  • 1.3 Forecast calculations
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Antiviral drugs market industry 360 degree synopsis
    • 2.1.1 Business trends
    • 2.1.2 Drug class trends
    • 2.1.3 Indication trends
    • 2.1.4 Type trends
    • 2.1.5 Age group trends
    • 2.1.6 Regional trends

Chapter 3 Antiviral Drugs Market Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2028 (USD Million)
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Rising prevalence of viral infections including COVID-19
      • 3.3.1.2 Increasing number of product launches for HIV treatment
      • 3.3.1.3 High investment in R&D activities and presence of pipeline products
      • 3.3.1.4 Increasing geriatric population
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Presence of generics
      • 3.3.2.2 Rising awareness about preventive drugs treatment
      • 3.3.2.3 Drug resistance
  • 3.4 Growth potential analysis
    • 3.4.1 By drug class
    • 3.4.2 By indication
    • 3.4.3 By type
    • 3.4.4 By age group
  • 3.5 COVID-19 impact analysis
  • 3.6 Regulatory landscape
  • 3.7 Porter's analysis
  • 3.8 Competitive landscape, 2021
  • 3.9 PESTEL analysis

Chapter 4 Antiviral Drugs Market, By Drug Class

  • 4.1 Key segment trends
  • 4.2 DNA polymerase inhibitors
    • 4.2.1 Market size, by region, 2017 - 2028 (USD Million)
  • 4.3 Reverse transcript inhibitors
    • 4.3.1 Market size, by region, 2017 - 2028 (USD Million)
  • 4.4 Protease inhibitors
    • 4.4.1 Market size, by region, 2017 - 2028 (USD Million)
  • 4.5 Neuraminidase inhibitors
    • 4.5.1 Market size, by region, 2017 - 2028 (USD Million)
  • 4.6 Others
    • 4.6.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 5 Antiviral Drugs Market, By Indication

  • 5.1 Key segment trends
  • 5.2 Influenza
    • 5.2.1 Market size, by region, 2017 - 2028 (USD Million)
  • 5.3 HIV AIDS
    • 5.3.1 Market size, by region, 2017 - 2028 (USD Million)
  • 5.4 Hepatitis
    • 5.4.1 Market size, by region, 2017 - 2028 (USD Million)
  • 5.5 Herpes simplex virus (HSV)
    • 5.5.1 Market size, by region, 2017 - 2028 (USD Million)
  • 5.6 Coronavirus infection
    • 5.6.1 Market size, by region, 2017 - 2028 (USD Million)
  • 5.7 Others
    • 5.7.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 6 Antiviral Drugs Market, By Type

  • 6.1 Key segment trends
  • 6.2 Branded
    • 6.2.1 Market size, by region, 2017 - 2028 (USD Million)
  • 6.3 Generic
    • 6.3.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 7 Antiviral Drugs Market, By Age Group

  • 7.1 Key segment trends
  • 7.2 Adult
    • 7.2.1 Market size, by region, 2017 - 2028 (USD Million)
  • 7.3 Pediatric
    • 7.3.1 Market size, by region, 2017 - 2028 (USD Million)
  • 7.4 Geriatric
    • 7.4.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 8 Antiviral Drugs Market, By Region

  • 8.1 Key regional trends
  • 8.2 North America
    • 8.2.1 Market size, by country, 2017 - 2028 (USD Million)
    • 8.2.2 Market size, by drug class, 2017 - 2028 (USD Million)
    • 8.2.3 Market size, by indication, 2017 - 2028 (USD Million)
    • 8.2.4 Market size, by type, 2017 - 2028 (USD Million)
    • 8.2.5 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.2.6 U.S.
      • 8.2.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.2.6.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.2.6.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.2.6.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.2.7 Canada
      • 8.2.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.2.7.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.2.7.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.2.7.4 Market size, by age group, 2017 - 2028 (USD Million)
  • 8.3 Europe
    • 8.3.1 Market size, by country, 2017 - 2028 (USD Million)
    • 8.3.2 Market size, by drug class, 2017 - 2028 (USD Million)
    • 8.3.3 Market size, by indication, 2017 - 2028 (USD Million)
    • 8.3.4 Market size, by type, 2017 - 2028 (USD Million)
    • 8.3.5 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.6 Germany
      • 8.3.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.6.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.6.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.6.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.7 UK
      • 8.3.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.7.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.7.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.7.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.8 France
      • 8.3.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.8.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.8.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.8.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.9 Spain
      • 8.3.9.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.9.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.9.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.9.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.10 Italy
      • 8.3.10.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.10.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.10.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.10.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.11 Russia
      • 8.3.11.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.11.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.11.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.11.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.12 Poland
      • 8.3.12.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.12.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.12.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.12.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.13 Switzerland
      • 8.3.13.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.13.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.13.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.13.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.14 The Netherlands
      • 8.3.14.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.14.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.14.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.14.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.3.15 Sweden
      • 8.3.15.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.3.15.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.3.15.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.3.15.4 Market size, by age group, 2017 - 2028 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Market size, by country, 2017 - 2028 (USD Million)
    • 8.4.2 Market size, by drug class, 2017 - 2028 (USD Million)
    • 8.4.3 Market size, by indication, 2017 - 2028 (USD Million)
    • 8.4.4 Market size, by type, 2017 - 2028 (USD Million)
    • 8.4.5 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.6 Japan
      • 8.4.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.6.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.6.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.6.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.7 China
      • 8.4.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.7.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.7.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.7.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.8 India
      • 8.4.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.8.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.8.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.8.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.9 Australia
      • 8.4.9.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.9.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.9.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.9.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.10 South Korea
      • 8.4.10.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.10.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.10.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.10.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.11 Singapore
      • 8.4.11.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.11.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.11.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.11.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.12 Indonesia
      • 8.4.12.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.12.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.12.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.12.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.13 Thailand
      • 8.4.13.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.13.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.13.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.13.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.14 Malaysia
      • 8.4.14.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.14.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.14.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.14.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.4.15 Philippines
      • 8.4.15.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.4.15.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.4.15.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.4.15.4 Market size, by age group, 2017 - 2028 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Market size, by country, 2017 - 2028 (USD Million)
    • 8.5.2 Market size, by drug class, 2017 - 2028 (USD Million)
    • 8.5.3 Market size, by indication, 2017 - 2028 (USD Million)
    • 8.5.4 Market size, by type, 2017 - 2028 (USD Million)
    • 8.5.5 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.5.6 Brazil
      • 8.5.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.5.6.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.5.6.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.5.6.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.5.7 Mexico
      • 8.5.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.5.7.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.5.7.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.5.7.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.5.8 Argentina
      • 8.5.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.5.8.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.5.8.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.5.8.4 Market size, by age group, 2017 - 2028 (USD Million)
  • 8.6 Middle East & Africa
    • 8.6.1 Market size, by country, 2017 - 2028 (USD Million)
    • 8.6.2 Market size, by drug class, 2017 - 2028 (USD Million)
    • 8.6.3 Market size, by indication, 2017 - 2028 (USD Million)
    • 8.6.4 Market size, by type, 2017 - 2028 (USD Million)
    • 8.6.5 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.6.6 Saudi Arabia
      • 8.6.6.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.6.6.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.6.6.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.6.6.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.6.7 South Africa
      • 8.6.7.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.6.7.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.6.7.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.6.7.4 Market size, by age group, 2017 - 2028 (USD Million)
    • 8.6.8 UAE
      • 8.6.8.1 Market size, by drug class, 2017 - 2028 (USD Million)
      • 8.6.8.2 Market size, by indication, 2017 - 2028 (USD Million)
      • 8.6.8.3 Market size, by type, 2017 - 2028 (USD Million)
      • 8.6.8.4 Market size, by age group, 2017 - 2028 (USD Million)

Chapter 9 Company Profiles

  • 9.1 Competitive dashboard, 2021
  • 9.2 Gilead Sciences, Inc
    • 9.2.1 Business overview
    • 9.2.2 Financial data
    • 9.2.3 Product landscape
    • 9.2.4 Strategic outlook
    • 9.2.5 SWOT analysis
  • 9.3 Johnson & Johnson
    • 9.3.1 Business overview
    • 9.3.2 Financial data
    • 9.3.3 Product landscape
    • 9.3.4 Strategic outlook
    • 9.3.5 SWOT analysis
  • 9.4 GlaxoSmithKline
    • 9.4.1 Business overview
    • 9.4.2 Financial data
    • 9.4.3 Product landscape
    • 9.4.4 Strategic outlook
    • 9.4.5 SWOT analysis
  • 9.5 AbbVie, Inc
    • 9.5.1 Business overview
    • 9.5.2 Financial data
    • 9.5.3 Product landscape
    • 9.5.4 Strategic outlook
    • 9.5.5 SWOT analysis
  • 9.6 Merck & Co.,
    • 9.6.1 Business overview
    • 9.6.2 Financial data
    • 9.6.3 Product landscape
    • 9.6.4 Strategic outlook
    • 9.6.5 SWOT analysis
  • 9.7 Bristol Myers Squibb
    • 9.7.1 Business overview
    • 9.7.2 Financial data
    • 9.7.3 Product landscape
    • 9.7.4 Strategic outlook
    • 9.7.5 SWOT analysis
  • 9.8 Aurobindo Pharma Limited
    • 9.8.1 Business overview
    • 9.8.2 Financial data
    • 9.8.3 Product landscape
    • 9.8.4 Strategic outlook
    • 9.8.5 SWOT analysis
  • 9.9 Sun Pharmaceutical Industries Ltd
    • 9.9.1 Business overview
    • 9.9.2 Financial data
    • 9.9.3 Product landscape
    • 9.9.4 Strategic outlook
    • 9.9.5 SWOT analysis
  • 9.10 Cipla, Inc.
    • 9.10.1 Business overview
    • 9.10.2 Financial data
    • 9.10.3 Product landscape
    • 9.10.4 Strategic outlook
    • 9.10.5 SWOT analysis
  • 9.11 Mylan N.V.
    • 9.11.1 Business overview
    • 9.11.2 Financial data
    • 9.11.3 Product landscape
    • 9.11.4 Strategic outlook
    • 9.11.5 SWOT analysis

Data Tables

  • TABLE 1 Antiviral drugs market, 2017 - 2021 (USD Million)
  • TABLE 2 Antiviral drugs market, 2022 - 2028 (USD Million)
  • TABLE 3 Antiviral drugs market, by drug class, 2017 - 2021 (USD Million)
  • TABLE 4 Antiviral drugs market, by drug class, 2022 - 2028 (USD Million)
  • TABLE 5 Antiviral drugs market, by indication, 2017 - 2021 (USD Million)
  • TABLE 6 Antiviral drugs market, by indication, 2022 - 2028 (USD Million)
  • TABLE 7 Antiviral drugs market, by type, 2017 - 2021 (USD Million)
  • TABLE 8 Antiviral drugs market, by type, 2022 - 2028 (USD Million)
  • TABLE 9 Antiviral drugs market, by age group, 2017 - 2021 (USD Million)
  • TABLE 10 Antiviral drugs market, by age group, 2022 - 2028 (USD Million)
  • TABLE 11 Antiviral drugs market, by region, 2017 - 2021 (USD Million)
  • TABLE 12 Antiviral drugs market, by region, 2022 - 2028 (USD Million)
  • TABLE 13 Industry impact forces
  • TABLE 14 DNA polymerase inhibitors market size, by region, 2017 - 2021 (USD Million)
  • TABLE 15 DNA polymerase inhibitors market size, by region, 2022 - 2028 (USD Million)
  • TABLE 16 Reverse transcriptase inhibitors market size, by region, 2017 - 2021 (USD Million)
  • TABLE 17 Reverse transcriptase inhibitors market size, by region, 2022 - 2028 (USD Million)
  • TABLE 18 Protease inhibitors market size, by region, 2017 - 2021 (USD Million)
  • TABLE 19 Protease inhibitors market size, by region, 2022 - 2028 (USD Million)
  • TABLE 20 Neuraminidase inhibitors market size, by region, 2017 - 2021 (USD Million)
  • TABLE 21 Neuraminidase inhibitors market size, by region, 2022 - 2028 (USD Million)
  • TABLE 22 Others market size, by region, 2017 - 2021 (USD Million)
  • TABLE 23 Others market size, by region, 2022 - 2028 (USD Million)
  • TABLE 24 Influenza market size, by region, 2017 - 2021 (USD Million)
  • TABLE 25 Influenza market size, by region, 2022 - 2028 (USD Million)
  • TABLE 26 HIV AIDS market size, by region, 2017 - 2021 (USD Million)
  • TABLE 27 HIV AIDS market size, by region, 2022 - 2028 (USD Million)
  • TABLE 28 Hepatitis market size, by region, 2017 - 2021 (USD Million)
  • TABLE 29 Hepatitis market size, by region, 2022 - 2028 (USD Million)
  • TABLE 30 Herpes simplex virus market size, by region, 2017 - 2021 (USD Million)
  • TABLE 31 Herpes simplex virus market size, by region, 2022 - 2028 (USD Million)
  • TABLE 32 Coronavirus infection market size, by region, 2017 - 2021 (USD Million)
  • TABLE 33 Coronavirus infection market size, by region, 2022 - 2028 (USD Million)
  • TABLE 34 Others market size, by region, 2017 - 2021 (USD Million)
  • TABLE 35 Others market size, by region, 2022 - 2028 (USD Million)
  • TABLE 36 Branded market size, by region, 2017 - 2021 (USD Million)
  • TABLE 37 Branded market size, by region, 2022 - 2028 (USD Million)
  • TABLE 38 Generic market size, by region, 2017 - 2021 (USD Million)
  • TABLE 39 Generic market size, by region, 2022 - 2028 (USD Million)
  • TABLE 40 Adult market size, by region, 2017 - 2021 (USD Million)
  • TABLE 41 Adult market size, by region, 2022 - 2028 (USD Million)
  • TABLE 42 Pediatric market size, by region, 2017 - 2021 (USD Million)
  • TABLE 43 Pediatric market size, by region, 2022 - 2028 (USD Million)
  • TABLE 44 Geriatric market size, by region, 2017 - 2021 (USD Million)
  • TABLE 45 Geriatric market size, by region, 2022 - 2028 (USD Million)
  • TABLE 46 North America market size, by country, 2017 - 2021 (USD Million)
  • TABLE 47 North America market size, by country, 2022 - 2028 (USD Million)
  • TABLE 48 North America market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 49 North America market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 50 North America market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 51 North America market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 52 North America market size, by type, 2017 - 2021 (USD Million)
  • TABLE 53 North America market size, by type, 2022 - 2028 (USD Million)
  • TABLE 54 North America market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 55 North America market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 56 U.S. market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 57 U.S. market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 58 U.S. market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 59 U.S. market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 60 U.S. market size, by type, 2017 - 2021 (USD Million)
  • TABLE 61 U.S. market size, by type, 2022 - 2028 (USD Million)
  • TABLE 62 U.S. market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 63 U.S. market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 64 Canada market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 65 Canada market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 66 Canada market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 67 Canada market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 68 Canada market size, by type, 2017 - 2021 (USD Million)
  • TABLE 69 Canada market size, by type, 2022 - 2028 (USD Million)
  • TABLE 70 Canada market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 71 Canada market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 72 Europe market size, by country, 2017 - 2021 (USD Million)
  • TABLE 73 Europe market size, by country, 2022 - 2028 (USD Million)
  • TABLE 74 Europe market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 75 Europe market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 76 Europe market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 77 Europe market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 78 Europe market size, by type, 2017 - 2021 (USD Million)
  • TABLE 79 Europe market size, by type, 2022 - 2028 (USD Million)
  • TABLE 80 Europe market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 81 Europe market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 82 Germany market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 83 Germany market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 84 Germany market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 85 Germany market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 86 Germany market size, by type, 2017 - 2021 (USD Million)
  • TABLE 87 Germany market size, by type, 2022 - 2028 (USD Million)
  • TABLE 88 Germany market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 89 Germany market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 90 UK market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 91 UK market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 92 UK market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 93 UK market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 94 UK market size, by type, 2017 - 2021 (USD Million)
  • TABLE 95 UK market size, by type, 2022 - 2028 (USD Million)
  • TABLE 96 UK market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 97 UK market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 98 France market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 99 France market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 100 France market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 101 France market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 102 France market size, by type, 2017 - 2021 (USD Million)
  • TABLE 103 France market size, by type, 2022 - 2028 (USD Million)
  • TABLE 104 France market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 105 France market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 106 Italy market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 107 Italy market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 108 Italy market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 109 Italy market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 110 Italy market size, by type, 2017 - 2021 (USD Million)
  • TABLE 111 Italy market size, by type, 2022 - 2028 (USD Million)
  • TABLE 112 Italy market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 113 Italy market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 114 Spain market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 115 Spain market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 116 Spain market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 117 Spain market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 118 Spain market size, by type, 2017 - 2021 (USD Million)
  • TABLE 119 Spain market size, by type, 2022 - 2028 (USD Million)
  • TABLE 120 Spain market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 121 Spain market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 122 Russia market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 123 Russia market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 124 Russia market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 125 Russia market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 126 Russia market size, by type, 2017 - 2021 (USD Million)
  • TABLE 127 Russia market size, by type, 2022 - 2028 (USD Million)
  • TABLE 128 Russia market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 129 Russia market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 130 Poland market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 131 Poland market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 132 Poland market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 133 Poland market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 134 Poland market size, by type, 2017 - 2021 (USD Million)
  • TABLE 135 Poland market size, by type, 2022 - 2028 (USD Million)
  • TABLE 136 Poland market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 137 Poland market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 138 Switzerland market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 139 Switzerland market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 140 Switzerland market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 141 Switzerland market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 142 Switzerland market size, by type, 2017 - 2021 (USD Million)
  • TABLE 143 Switzerland market size, by type, 2022 - 2028 (USD Million)
  • TABLE 144 Switzerland market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 145 Switzerland market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 146 Netherlands market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 147 Netherlands market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 148 Netherlands market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 149 Netherlands market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 150 Netherlands market size, by type, 2017 - 2021 (USD Million)
  • TABLE 151 Netherlands market size, by type, 2022 - 2028 (USD Million)
  • TABLE 152 Netherlands market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 153 Netherlands market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 154 Sweden market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 155 Sweden market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 156 Sweden market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 157 Sweden market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 158 Sweden market size, by type, 2017 - 2021 (USD Million)
  • TABLE 159 Sweden market size, by type, 2022 - 2028 (USD Million)
  • TABLE 160 Sweden market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 161 Sweden market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 162 Asia Pacific market size, by country, 2017 - 2021 (USD Million)
  • TABLE 163 Asia Pacific market size, by country, 2022 - 2028 (USD Million)
  • TABLE 164 Asia Pacific market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 165 Asia Pacific market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 166 Asia Pacific market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 167 Asia Pacific market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 168 Asia Pacific market size, by type, 2017 - 2021 (USD Million)
  • TABLE 169 Asia Pacific market size, by type, 2022 - 2028 (USD Million)
  • TABLE 170 Asia Pacific market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 171 Asia Pacific market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 172 Japan market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 173 Japan market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 174 Japan market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 175 Japan market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 176 Japan market size, by type, 2017 - 2021 (USD Million)
  • TABLE 177 Japan market size, by type, 2022 - 2028 (USD Million)
  • TABLE 178 Japan market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 179 Japan market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 180 China market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 181 China market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 182 China market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 183 China market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 184 China market size, by type, 2017 - 2021 (USD Million)
  • TABLE 185 China market size, by type, 2022 - 2028 (USD Million)
  • TABLE 186 China market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 187 China market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 188 India market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 189 India market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 190 India market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 191 India market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 192 India market size, by type, 2017 - 2021 (USD Million)
  • TABLE 193 India market size, by type, 2022 - 2028 (USD Million)
  • TABLE 194 India market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 195 India market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 196 Australia market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 197 Australia market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 198 Australia market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 199 Australia market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 200 Australia market size, by type, 2017 - 2021 (USD Million)
  • TABLE 201 Australia market size, by type, 2022 - 2028 (USD Million)
  • TABLE 202 Australia market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 203 Australia market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 204 South Korea market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 205 South Korea market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 206 South Korea market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 207 South Korea market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 208 South Korea market size, by type, 2017 - 2021 (USD Million)
  • TABLE 209 South Korea market size, by type, 2022 - 2028 (USD Million)
  • TABLE 210 South Korea market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 211 South Korea market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 212 Singapore market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 213 Singapore market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 214 Singapore market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 215 Singapore market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 216 Singapore market size, by type, 2017 - 2021 (USD Million)
  • TABLE 217 Singapore market size, by type, 2022 - 2028 (USD Million)
  • TABLE 218 Singapore market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 219 Singapore market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 220 Indonesia market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 221 Indonesia market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 222 Indonesia market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 223 Indonesia market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 224 Indonesia market size, by type, 2017 - 2021 (USD Million)
  • TABLE 225 Indonesia market size, by type, 2022 - 2028 (USD Million)
  • TABLE 226 Indonesia market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 227 Indonesia market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 228 Thailand market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 229 Thailand market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 230 Thailand market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 231 Thailand market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 232 Thailand market size, by type, 2017 - 2021 (USD Million)
  • TABLE 233 Thailand market size, by type, 2022 - 2028 (USD Million)
  • TABLE 234 Thailand market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 235 Thailand market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 236 Malaysia market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 237 Malaysia market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 238 Malaysia market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 239 Malaysia market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 240 Malaysia market size, by type, 2017 - 2021 (USD Million)
  • TABLE 241 Malaysia market size, by type, 2022 - 2028 (USD Million)
  • TABLE 242 Malaysia market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 243 Malaysia market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 244 Philippines market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 245 Philippines market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 246 Philippines market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 247 Philippines market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 248 Philippines market size, by type, 2017 - 2021 (USD Million)
  • TABLE 249 Philippines market size, by type, 2022 - 2028 (USD Million)
  • TABLE 250 Philippines market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 251 Philippines market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 252 Latin America market size, by country, 2017 - 2021 (USD Million)
  • TABLE 253 Latin America market size, by country, 2022 - 2028 (USD Million)
  • TABLE 254 Latin America market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 255 Latin America market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 256 Latin America market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 257 Latin America market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 258 Latin America market size, by type, 2017 - 2021 (USD Million)
  • TABLE 259 Latin America market size, by type, 2022 - 2028 (USD Million)
  • TABLE 260 Latin America market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 261 Latin America market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 262 Brazil market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 263 Brazil market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 264 Brazil market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 265 Brazil market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 266 Brazil market size, by type, 2017 - 2021 (USD Million)
  • TABLE 267 Brazil market size, by type, 2022 - 2028 (USD Million)
  • TABLE 268 Brazil market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 269 Brazil market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 270 Mexico market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 271 Mexico market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 272 Mexico market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 273 Mexico market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 274 Mexico market size, by type, 2017 - 2021 (USD Million)
  • TABLE 275 Mexico market size, by type, 2022 - 2028 (USD Million)
  • TABLE 276 Mexico market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 277 Mexico market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 278 Argentina market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 279 Argentina market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 280 Argentina market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 281 Argentina market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 282 Argentina market size, by type, 2017 - 2021 (USD Million)
  • TABLE 283 Argentina market size, by type, 2022 - 2028 (USD Million)
  • TABLE 284 Argentina market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 285 Argentina market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 286 MEA market size, by country, 2017 - 2021 (USD Million)
  • TABLE 287 MEA market size, by country, 2022 - 2028 (USD Million)
  • TABLE 288 MEA market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 289 MEA market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 290 MEA market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 291 MEA market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 292 MEA market size, by type, 2017 - 2021 (USD Million)
  • TABLE 293 MEA market size, by type, 2022 - 2028 (USD Million)
  • TABLE 294 MEA market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 295 MEA market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 296 South Africa market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 297 South Africa market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 298 South Africa market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 299 South Africa market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 300 South Africa market size, by type, 2017 - 2021 (USD Million)
  • TABLE 301 South Africa market size, by type, 2022 - 2028 (USD Million)
  • TABLE 302 South Africa market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 303 South Africa market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 304 Saudi Arabia market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 305 Saudi Arabia market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 306 Saudi Arabia market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 307 Saudi Arabia market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 308 Saudi Arabia market size, by type, 2017 - 2021 (USD Million)
  • TABLE 309 Saudi Arabia market size, by type, 2022 - 2028 (USD Million)
  • TABLE 310 Saudi Arabia market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 311 Saudi Arabia market size, by age group, 2022 - 2028 (USD Million)
  • TABLE 312 UAE market size, by drug class, 2017 - 2021 (USD Million)
  • TABLE 313 UAE market size, by drug class, 2022 - 2028 (USD Million)
  • TABLE 314 UAE market size, by indication, 2017 - 2021 (USD Million)
  • TABLE 315 UAE market size, by indication, 2022 - 2028 (USD Million)
  • TABLE 316 UAE market size, by type, 2017 - 2021 (USD Million)
  • TABLE 317 UAE market size, by type, 2022 - 2028 (USD Million)
  • TABLE 318 UAE market size, by age group, 2017 - 2021 (USD Million)
  • TABLE 319 UAE market size, by age group, 2022 - 2028 (USD Million)

Charts & Figures

  • FIG. 1 Antiviral drugs industry 36 degree synopsis, 2017 - 2028
  • FIG. 2 Industry segmentation
  • FIG. 3 Antiviral drugs industry landscape, 2017 - 2028 (USD Million)
  • FIG. 4 Growth potential analysis, by drug class
  • FIG. 5 Growth potential analysis, by indication
  • FIG. 6 Growth potential analysis, by type
  • FIG. 7 Growth potential analysis, by age group
  • FIG. 8 Porter's analysis
  • FIG. 9 PESTEL analysis
  • FIG. 10 Key segment trends, by drug class
  • FIG. 11 Key segment trends, by indication
  • FIG. 12 Key segment trends, by type
  • FIG. 13 Key segment trends, by age group
  • FIG. 14 Key regional trends
  • FIG. 15 Competitive dashboard, 2021